Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9YT | ISIN: ES0169501022 | Ticker-Symbol: PMRA
Tradegate
05.06.25 | 17:11
91,55 Euro
+1,10 % +1,00
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
91,4091,4505.06.
91,5091,5505.06.

Aktuelle News zur PHARMAMAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PHARMAMAR Aktie jetzt für 0€ handeln
DiPharmaMar präsentiert auf der ASCO dass Zepzelca® (lurbinectedin) in Kombination mit Atezolizumab (Tecentriq®) das Überleben als Erstlinien-Erhaltungstherapie bei kleinzelligem Lungenkrebs208Madrid (ots/PRNewswire) - - Die Erstlinien-Erhaltungskombinationstherapie verringerte das Risiko eines Fortschreitens der Krankheit oder des Todes um 46%, mit einer medianen Gesamtüberlebenszeit von...
► Artikel lesen
DiPHARMA MAR, S.A.: Pharma Mar presents in ASCO positive results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer.5
DiPharmaMar presents at ASCO that the Zepzelca(lurbinectedin) and atezolizumab (Tecentriq) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer224First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from...
► Artikel lesen
MoPHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 26 May and 30 May 2025.2
26.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 19 May and 23 May 2025.2
26.05.ASCO 25: Jazz, PharmaMar reveal SCLC survival data5
21.05.PHARMA MAR, S.A.: The Company has submitted EU marketing authorization application for lurbinectedin in combination with atezolizumab in first-line maintenance therapy for extensive-stage small cell lung cancer.3
19.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 12 May and 16 May 2025.2
19.05.PHARMA MAR, S.A.: The Company announces that its partner Adium Pharma S.A. has received approval for commercialization for Zepzelca® (lurbinectedina) in Argentina.3
12.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 5 May and 9 May 2025.3
06.05.PHARMA MAR, S.A.: The Company sends notice of the Ordinary General Shareholders' Meeting and proposed resolutions.3
05.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 28 April and 2 May 2025.3
29.04.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 22 April and 25 April 20252
24.04.PHARMA MAR, S.A.: The Company files first quarter 2025 financial information.4
24.04.PHARMA MAR, S.A.: The Company announces the decision of the Board of Directors to call the Ordinary General Shareholders' Meeting on June 17, 2025 and June 18, 2025, respectively, on the first and second call notice.3
21.04.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 14 April and 17 April 2025.1
14.04.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 7 April and 11 April 2025.3
07.04.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 31 March and 4 April 2025.2
04.04.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 25 and 28 February 2025.5
04.04.PHARMA MAR, S.A.: EthiFinance Ratings maintains long-term credit rating of Pharma Mar.2
Seite:  Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1